Daytrading, Eminis, Forex trading, Swing Trading STOCK ALERT - 490674
Andy Jones  |  by www.tradingmarkets.com. All rights reserved. 13.11 | 23:23

Receive Dave's best setups each evening from his favorite trading patterns.

Let Gary Kaltbaum send you timely emails to alrt when breakouts occure.
Every day receive the best plan of attack for the next day's trading directly from professional trader Kevin Haggerty.

(RTTNews) - Isis Pharmaceuticals Inc. ( | | | ), a biopharmaceutical company, announced new results from two Phase 2 clinical trials of ISIS 301012 presented at the American Heart Association Annual Scientific Sessions in Chicago. The company said that in the first study reported, patients with high cholesterol on stable doses of statins were treated with ISIS 301012 for five weeks.

Patients who received 300 mg/week of ISIS 301012 in this study achieved a 51% reduction in LDL-cholesterol ( | | | ), a 42% reduction in total cholesterol ( | | | ), and a 41% reduction in triglycerides ( | | | ) beyond the levels achieved with statins alone. Isis Pharmaceuticals, Inc. is rising in trading before the bell on Monday.

The stock is $3.02 on 2.1 million K shares.

Isis Pharmaceuticals Inc. traded in a range for the majority of Friday's session. The stock finished up .

34 at 81.06. The stock finished at the lower end of a 3 1/2 week range.

Read more on by www.tradingmarkets.com. All rights reserved.
Keywords: Isis Pharmaceuticals, Pharmaceuticals Inc, Isis Pharmaceuticals Inc
Related news
Post comments
Name
Place
1 + 1 =
Comments